Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids)Gabrielle Norrish, Juan Pablo Kaski, Terence Prendiville et al.|JAMA Cardiology|2019Cited by 248
Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy RegistryLia Crotti, Peter J. Schwartz, Carla Spazzolini et al.|European Heart Journal|2019Cited by 184
The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathyGabrielle Norrish, Rumana Omar, Constantin‐Cristian Topriceanu et al.|European Journal of Preventive Cardiology|2021Cited by 35
Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathyConstantin‐Cristian Topriceanu, Gabrielle Norrish, Ella Field et al.|International Journal of Cardiology|2022Cited by 11
Contemporary practice and resource availability for genetic testing in paediatric hypertrophic cardiomyopathyChristoph P. Hofmann, Gabrielle Norrish, Sabine Klaassen et al.|Journal of Medical Genetics|2025Cited by 2